shanghai denovo officially launches phase i clinical study of a new tlr8 agonist dn1508052-pg麻将胡了模拟器

1906
issuing time:2020-09-17 11:13

on september 10, shanghai denovo pharmaceuticaltechnology co., ltd., a subsidiary of qingfeng pharmaceutical group, held atlr8 agonist dn1508052-01 phase i clinical trial kick-off meeting at shanghaidongfang hospital, officially launching the project's phase i clinical study.



xw202009173.png



xw202009172.png


prev
next
article classification:
share to:
qingfeng pharmaceutical group co.ltd
location:8 zhandong av., zhanggong, ganzhou, jiangxi province, china
phone: 86-0797-5560800,5560600 fax: 86-0797-5560620
网站地图